1. Home
  2. CISO vs SCYX Comparison

CISO vs SCYX Comparison

Compare CISO & SCYX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CISO
  • SCYX
  • Stock Information
  • Founded
  • CISO 2015
  • SCYX 1999
  • Country
  • CISO United States
  • SCYX United States
  • Employees
  • CISO N/A
  • SCYX N/A
  • Industry
  • CISO Computer Software: Prepackaged Software
  • SCYX Biotechnology: Pharmaceutical Preparations
  • Sector
  • CISO Technology
  • SCYX Health Care
  • Exchange
  • CISO Nasdaq
  • SCYX Nasdaq
  • Market Cap
  • CISO 31.4M
  • SCYX 28.5M
  • IPO Year
  • CISO N/A
  • SCYX 2014
  • Fundamental
  • Price
  • CISO $1.00
  • SCYX $0.75
  • Analyst Decision
  • CISO
  • SCYX
  • Analyst Count
  • CISO 0
  • SCYX 0
  • Target Price
  • CISO N/A
  • SCYX N/A
  • AVG Volume (30 Days)
  • CISO 897.9K
  • SCYX 176.2K
  • Earning Date
  • CISO 08-13-2025
  • SCYX 08-07-2025
  • Dividend Yield
  • CISO N/A
  • SCYX N/A
  • EPS Growth
  • CISO N/A
  • SCYX N/A
  • EPS
  • CISO N/A
  • SCYX N/A
  • Revenue
  • CISO $29,887,603.00
  • SCYX $2,630,000.00
  • Revenue This Year
  • CISO N/A
  • SCYX $463.61
  • Revenue Next Year
  • CISO N/A
  • SCYX $310.80
  • P/E Ratio
  • CISO N/A
  • SCYX N/A
  • Revenue Growth
  • CISO N/A
  • SCYX N/A
  • 52 Week Low
  • CISO $0.26
  • SCYX $0.66
  • 52 Week High
  • CISO $3.84
  • SCYX $2.29
  • Technical
  • Relative Strength Index (RSI)
  • CISO 42.73
  • SCYX 57.99
  • Support Level
  • CISO $1.00
  • SCYX $0.67
  • Resistance Level
  • CISO $1.24
  • SCYX $0.83
  • Average True Range (ATR)
  • CISO 0.09
  • SCYX 0.04
  • MACD
  • CISO -0.03
  • SCYX 0.02
  • Stochastic Oscillator
  • CISO 7.67
  • SCYX 94.12

About CISO CISO Global Inc.

CISO Global Inc provides cybersecurity services. The services are used to protect client's data, financial information, intellectual property, and business reputation. The services include penetration testing, security remediation, compliance auditing, vulnerability assessment, and others. Geographically, the company operates in U.S., Chile and All other countries. The maximum revenue is generated from U.S.

About SCYX SCYNEXIS Inc.

SCYNEXIS Inc is a drug development company that focuses on the development and commercialization of novel anti-infectives to address unmet therapeutic needs. It is engaged in developing a product candidate, ibrexafungerp which is a novel oral and intravenous (IV) drug for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections. The ibrexafungerp is a novel and structurally distinct triterpenoid glucan synthase inhibitor that is effective in vitro and in vivo against broad range of Candida and Aspergillus species, including drug-resistant strains as well as Pneumocystis, Coccidioides, Histoplasma and Blastomyces genera and some common mucorales species.

Share on Social Networks: